Jim Boeheim and Cellceutix (CTIX) Team to Fight Cancer
Clinical trials should be starting at Harvard's Dana-Farber Cancer Center in the next two months as Cellceutix looks to validate their laboratory research on Kevetrin, their novel drug in development for the treatment of drug resistant cancers. Yesterday, it was disclosed that Syracuse basketball icon Jim Boeheim has come on board the Cellceutix team in the fight against cancer.
(GCA, DSCO, ADGF) PennyOmega.com Watch List for Wed Mar. 07, 2012
Cellceutix Featured on Front Page of Boston Business Journal
Cellceutix continues to gain industry attention by both investors, big pharma and publications. Their Chief Executive Officer was featured on the front page of Friday's Boston Business Journal. As the clinical trials for Kevetrin should be starting in a couple months at Dana-Farber, attention should continue to increase.
SDIX, CRWE, SBGI, XATA, SEAC Stock Market Report from PennyOtcStock
SDIX? (NASDAQ: SDIX), recently announced that it has successfully completed its previously announced sale of the assets of its water quality division to Modern Water plc for $4.5 million. Modern Water acquired the division's intellectual property, current inventory and commercial contracts, as well as its equipment and staff.
Why Athersys (ATHX) Is A Compelling Investment Opportunity
Athersys Inc. (NASDAQ: ATHX) is a company focused on regenerative medicine, similar to companies like Osiris Therapeutics Inc. (NASDAQ: OSIR), Mesoblast (ASX:MSB), and Cytori (NASDQ: CYTX) and others that are developing a stem cell platform to target a range of disease indications.
Identifying Compelling Investment Opportunities In The Biotechnology Sector
How does an investor measure the potential value of a new therapy or technology? From a financial perspective, the classical approach is to consider the following questions:
v How large is the potential market for a given product, in terms of number of potential patients, and potential dollar value?